Mizuho Securities analyst Difei Yang maintained a Hold rating on Spark Therapeutics (ONCE) today and set a price target of $114.50. The company’s shares closed last Monday at $104.80, close to its 52-week high of $114.20.
Yang wrote:
“We hosted an expert event last week to discuss the pending acquisition of Roche (RHHBY, Not-covered). We discussed the probability of success for the deal to close following numerous delays due to FTC requests as well as potential divestiture requirement(s). Bottom line: while there isn’t necessarily a good merit-based argument to be made in favor of a divestiture, based on recent developments including: three “pull and re-files” of the HSR filing; a 2nd request by the FTC; and the extension of the walk date; a divestiture seems more likely than not, although the best candidate/asset remains a point of debate. Overall, we believe the deal is more likely to close than not.”
According to TipRanks.com, Yang is a 4-star analyst with an average return of 4.3% and a 39.4% success rate. Yang covers the Healthcare sector, focusing on stocks such as Xeris Pharmaceuticals Inc, Alder Biopharmaceuticals, and Audentes Therapeutics.
The word on The Street in general, suggests a Hold analyst consensus rating for Spark Therapeutics with a $114.50 average price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $114.20 and a one-year low of $34.53. Currently, Spark Therapeutics has an average volume of 421.4K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Spark Therapeutics, Inc. engages in the research, development, and commercialization of gene therapies. Its product portfolio intends to treat inherited retinal sickness, liver-mediated, and neurodegenerative diseases.
